SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 125-130

  Kuo, Shou Jen ^a,b   Lin, Hui Yi ^c   Chien, Su Yu ^a   Chen, Dar Ren ^a,b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bcl 2; Breast cancer; Ki67; Silent mating type information regulation 2 homologue 1

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; SIRTINOL; SIRTUIN 1;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CELL STRAIN MCF 7; CELL SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION;

BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MCF-7 CELLS; NAPHTHOLS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIRTUIN 1;

EID: 84878184564     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2470     Document Type: Article

References (35)

1. Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435, 2004. (Pubitemid 39050375)
2. Michan S and Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13, 2007. (Pubitemid 46788079)
3. Vaziri H, Dessain SK, Ng Eaton E, et al: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159, 2001. (Pubitemid 33035942)
4. Dai JM, Wang ZY, Sun DC, Lin RX and Wang SQ: SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol 210: 161-166, 2007.
5. Wong S and Weber JD: Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J 407: 451-460, 2007. (Pubitemid 350058478)
6. Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618, 2007. (Pubitemid 47105506)
7. Jung-Hynes B and Ahmad N: Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 8: 1478-1483, 2009.
8. Kuzmichev A, Margueron R, Vaquero A, et al: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102: 1859-1864, 2005. (Pubitemid 40261977)
9. Zhang Y, Zhang M, Dong H, et al: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 28: 445-460, 2009.
10. Stünkel W, Peh BK, Tan YC, et al: Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2: 1360-1368, 2007. (Pubitemid 350176266)
11. Kabra N, Li Z, Chen L, et al: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 284: 18210-18217, 2009.
12. + cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
13. Jang KY, Hwang SH, Kwon KS, et al: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32: 1523-1531, 2008.
14. Bradbury CA, Khanim FL, Hayden R, et al: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19: 1751-1759, 2005. (Pubitemid 41486152)
15. Yuan Z, Zhang X, Sengupta N, Lane WS and Seto E: SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell 27: 149-162, 2007. (Pubitemid 46991383)
16. Chu F, Chou PM, Zheng X, Mirkin BL and Rebbaa A: Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65: 10183-10187, 2005. (Pubitemid 41743708)
17. Cheng HL, Mostoslavsky R, Saito S, et al: Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100: 10794-10799, 2003. (Pubitemid 37140107)
18. Matsushita N, Takami Y, Kimura M, et al: Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 10: 321-332, 2005. (Pubitemid 40443684)
19. Kojima K, Ohhashi R, Fujita Y, et al: A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373: 423-428, 2008.
20. Yuan J, Minter-Dykhouse K and Lou Z: A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 185: 203-211, 2009.
21. Firestein R, Blander G, Michan S, et al: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3: e2020, 2008.
22. Chua KF, Mostoslavsky R, Lombard DB, et al: Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2: 67-76, 2005. (Pubitemid 43239826)
23. Wang RH, Sengupta K, Li C, et al: Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323, 2008.
24. Lim CS: SIRT1: tumor promoter or tumor suppressor? Med Hypotheses 67: 341-344, 2006.
25. Li K and Luo J: The role of SIRT1 in tumorigenesis. N Am J Med Sci 4: 104-106, 2011.
26. Tavassoli FA and Devilee P (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, 2003.
27. Sung JY, Kim R, Kim JE and Lee J: Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 101: 1738-1744, 2010.
28. Heltweg B, Gatbonton T, Schuler AD, et al: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368-4377, 2006.
29. Ota H, Tokunaga E, Chang K, et al: Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25: 176-185, 2006. (Pubitemid 43083679)
30. Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457-10463, 2005. (Pubitemid 41743740)
31. Reed JC: Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330, 2008.
32. Hockenbery DM: Targeting mitochondria for cancer therapy. Environ Mol Mutagen 51: 476-489, 2010.
33. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC and Fornace AJ Jr: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60: 6101-6110, 2000.
34. Zhang M, Guo R, Zhai Y and Yang D: LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members. Cancer Lett 195: 201-210, 2003. (Pubitemid 36603330)
35. Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18: 1414-1424, 2011.